why choose us

First received: February 09, 2024

Clinical Trial: SGB for COVID-induced Parosmia

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: COVID-19-Induced Parosmia

Study Type: INTERVENTIONAL


Official Title: Stellate Ganglion Block for the Treatment of COVID-19-Induced Parosmia: Double-Blinded, Placebo-Controlled Randomized Clinical Trial

Brief Summary: Chronic olfactory dysfunction, both hyposmia and parosmia, from the COVID-19 pandemic is a growing public health crisis with up to 1.2 million people in the United States affected.Olfactory dysfunction impacts one's quality of life significantly by decreasing the enjoyment of foods, creating environmental safety concerns, and affecting one's ability to perform certain jobs.Olfactory loss is also an independent predictor of anxiety, depression, and even mortality.Recent research by our group (unpublished…

Read more